Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
e-Health and multiple sclerosis: An update.
Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, Abbadessa G, Schmierer K, Solaro C, Prosperini L, Tedeschi G, Giovannoni G, Bonavita S. Lavorgna L, et al. Among authors: lanzillo r. Mult Scler. 2018 Nov;24(13):1657-1664. doi: 10.1177/1352458518799629. Epub 2018 Sep 19. Mult Scler. 2018. PMID: 30231004 Review.
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V. Lanzillo R, et al. Mult Scler. 2010 Apr;16(4):450-4. doi: 10.1177/1352458509358909. Epub 2010 Feb 11. Mult Scler. 2010. PMID: 20150398 Clinical Trial.
Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.
Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, Lus G, Rinaldi F, Rocca MA, Trojano M, Bianchi A, Comi G, Filippi M; Italian MS Study Group. Ghezzi A, et al. Mult Scler. 2013 Jul;19(8):1106-12. doi: 10.1177/1352458512471878. Epub 2013 Feb 11. Mult Scler. 2013. PMID: 23401129
Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.
Lavorgna L, Bonavita S, Ippolito D, Lanzillo R, Salemi G, Patti F, Valentino P, Coniglio G, Buccafusca M, Paolicelli D, d'Ambrosio A, Bresciamorra V, Savettieri G, Zappia M, Alfano B, Gallo A, Simone I, Tedeschi G. Lavorgna L, et al. Among authors: lanzillo r. Mult Scler. 2014 Feb;20(2):220-6. doi: 10.1177/1352458513494958. Epub 2013 Jul 9. Mult Scler. 2014. PMID: 23838177
Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L. Clerico M, et al. Among authors: lanzillo r. JAMA Neurol. 2014 Aug;71(8):954-60. doi: 10.1001/jamaneurol.2014.1200. JAMA Neurol. 2014. PMID: 24977406 Clinical Trial.
Uric acid: a potential biomarker of multiple sclerosis and of its disability.
Moccia M, Lanzillo R, Palladino R, Russo C, Carotenuto A, Massarelli M, Vacca G, Vacchiano V, Nardone A, Triassi M, Morra VB. Moccia M, et al. Among authors: lanzillo r. Clin Chem Lab Med. 2015 Apr;53(5):753-9. doi: 10.1515/cclm-2014-0744. Clin Chem Lab Med. 2015. PMID: 25241733
247 results